Authors

Latest:

Dr Vahdat on the Role of Copper Depletion in Reducing Metastatic Disease Risk in TNBC

Linda Vahdat, MD, MBA, discusses the role of copper depletion in reducing the risk of metastatic disease development in triple-negative breast cancer.

Timothy Craig Allen, MD, JD, FCAP

Latest:

Novel HER2-Targeted Therapies for NSCLC

Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.

Gao-Jun Teng, MD

Latest:

Dr Teng on the Phase 2 CARES-005 Study of TACE Plus Camrelizumab and Rivoceranib in Unresectable HCC

Gao-Jun Teng, MD, discusses findings from the phase 2 CARES-005 trial of TACE plus camrelizumab and rivoceranib vs TACE alone in patients with unresectable HCC.

Chun Chao, PhD, MS

Latest:

Dr Chao on the Correlation Between Broad-Spectrum Antibiotics and Early-Onset CRC

Chun Chao, PhD, MS, discusses the association between the use of broad-spectrum antibiotics and the risk of developing early-onset colorectal cancer.

Katerina Politi, PhD

Latest:

Dr. Politi on Drug-Tolerant Persister Cells in Cancer Care

Katerina Politi, PhD, discusses drug-tolerant persister cells in patients with cancer.

Gregory W. Roloff, MD

Latest:

Key Takeaways and Clinical Pearls in the Treatment of R/R ALL

The key opinion leaders provide concluding insights and essential recommendations regarding the management of relapsed/refractory acute lymphoblastic leukemia.

Moshe Ornstein, MD, MA

Latest:

Dr Ornstein on the Use of IO/TKI Doublets in Non-ccRCC

Moshe Ornstein, MD, MA, discusses the use of first-line IO/TKI doublet regimens in patients with non–clear cell renal cell carcinoma.

Michele Ghidini, MD, PhD

Latest:

Dr. Ghidini on the Effects of Body Weight Loss in Gastric/GEJ Cancer

Michele Ghidini, MD, PhD, discusses the effects of body weight loss in gastric/gastroesophageal junction cancer.

Carsten Niemann, MD, PhD

Latest:

Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines

Panelists discuss the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates.

Tondre Buck, MD

Latest:

Disparities in Multiple Myeloma Care: The Path Toward Health Equity

Expert panelists share their closing thoughts on the path to improve health equity in multiple myeloma management for racial and ethnic minority groups.

Steven P. Treon, MD, PhD

Latest:

Dr. Treon on the Evolution of BTK Inhibitors in Waldenström Macroglobulinemia

Steven P. Treon, MD, PhD, discusses the role of BTK inhibitors in Waldenström macroglobulinemia.

Heather McArthur, MD, MPH

Latest:

Looking Ahead: Expert Future Perspectives in HR+ Breast Cancer

In their concluding remarks, Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, summarize their key insights and perspectives on the management of HR+ breast cancer.

Thomas E. Hutson, DO

Latest:

Dr Hutson on the Final OS Analysis of the CLEAR Study in Advanced RCC

Thomas Hutson, DO, discusses the final prespecified overall survival analysis of the phase 3 CLEAR study in patients with advanced renal cell carcinoma.

Andrew Ip, MD

Latest:

Dr Ip on Real-World Data Informing CAR T-Cell Therapy Selection in LBCL

Andrew Ip, MD, discusses the importance of making informed clinical decisions when selecting CAR T-cell therapy in older vs younger patients with LBCL.

Katherine Tkaczuk, MD

Latest:

Dr. Tkaczuk on the Utilization of Trastuzumab Deruxtecan in HER2+ Breast Cancer

Katherine Tkaczuk, MD, discusses the utilization of trastuzumab deruxtecan in HER2-positive breast cancer.

Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center

Latest:

Unmet Needs and Looking Ahead in Essential Thrombocythemia

Unmet needs and current areas that are being studied in in essential thrombocythemia.

Jessica Yasmine Islam, PhD, MPH

Latest:

Dr Islam on Treatment of Patients With Hodgkin Lymphoma With or Without HIV

Jessica Yasmine Islam, PhD, MPH, discusses the treatment of patients with Hodgkin’s lymphoma who do or do not have HIV.

Marianne Pavel, MD

Latest:

Dr. Pavel on the PFS With Lanreotide Autogel in the CLARINET FORTE Trial

Marianne Pavel, MD, discusses the progression-free survival of patients with pancreatic and midgut neuroendocrine tumors who are treated with lanreotide autogel in the phase 2 CLARINET FORTE trial.

Elisa Ten Hacken, PhD

Jean-Marc Classe, MD, PhD

Latest:

Dr Classe on Lymphadenectomy Omission in Advanced Epithelial Ovarian Cancer

Jean-Marc Classe, MD, PhD, discusses lymphadenectomy omission following cytoreductive surgery after chemotherapy in advanced epithelial ovarian cancer.